Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Crinetics Pharmaceuticals Inc

CRNX
Current price
33.4 USD +0.99 USD (+3.05%)
Last closed 32.74 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 2 187 009 280 USD
Yield for 12 month +82.31 %
Week
Month
Year
CRNX
21.11.2021 - 28.11.2021

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). It is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. The company was incorporated in 2008 and is headquartered in San Diego, California. Address: Building No. 2, San Diego, CA, United States, 92121

Analytics

WallStreet Target Price

46.82 USD

P/E ratio

Dividend Yield

Current Year

+4 737 000 USD

Last Year

+1 078 000 USD

Current Quarter

+346 000 USD

Last Quarter

+988 000 USD

Current Year

+4 737 000 USD

Last Year

+1 078 000 USD

Current Quarter

+346 000 USD

Last Quarter

+988 000 USD

Key Figures CRNX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -206 390 000 USD
Operating Margin TTM -17045.38 %
PE Ratio
Return On Assets TTM -25.27 %
PEG Ratio
Return On Equity TTM -44.36 %
Wall Street Target Price 46.82 USD
Revenue TTM 4 722 000 USD
Book Value 8.21 USD
Revenue Per Share TTM 0.086 USD
Dividend Share
Quarterly Revenue Growth YOY -24.5 %
Dividend Yield
Gross Profit TTM -125 488 000 USD
Earnings Share -3.64 USD
Diluted Eps TTM -3.64 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CRNX

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CRNX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation CRNX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 356.7399
Price Sales TTM 463.1532
Enterprise Value EBITDA -8.1619
Price Book MRQ 3.9927

Financials CRNX

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators CRNX

For 52 weeks

15.23 USD 33.2 USD
50 Day MA 28.98 USD
Shares Short Prior Month 6 710 555
200 Day MA 21.82 USD
Short Ratio 7.31
Shares Short 6 201 777
Short Percent 10.35 %